These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11409581)

  • 1. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of Mycobacterium malmoense determined at the growth optimum pH (pH 6.0).
    Heginbothom ML; Lindholm-Levy PJ; Heifets LB
    Int J Tuberc Lung Dis; 1998 May; 2(5):430-4. PubMed ID: 9613641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
    Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
    Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
    Akselband Y; Cabral C; Shapiro DS; McGrath P
    J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
    van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
    Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands.
    van Ingen J; van der Laan T; Dekhuijzen R; Boeree M; van Soolingen D
    Int J Antimicrob Agents; 2010 Feb; 35(2):169-73. PubMed ID: 20006470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of ethambutol MICs for Mycobacterium tuberculosis and Mycobacterium avium isolates by resazurin microtitre assay.
    Jadaun GP; Agarwal C; Sharma H; Ahmed Z; Upadhyay P; Faujdar J; Gupta AK; Das R; Gupta P; Chauhan DS; Sharma VD; Katoch VM
    J Antimicrob Chemother; 2007 Jul; 60(1):152-5. PubMed ID: 17483147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium fortuitum infections: a review with two illustrative cases.
    Halpern AA; Nagel DA
    Clin Orthop Relat Res; 1978 Oct; (136):247-52. PubMed ID: 729293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
    Tsukamura M
    Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.
    van Ingen J; Totten SE; Heifets LB; Boeree MJ; Daley CL
    Int J Antimicrob Agents; 2012 Feb; 39(2):173-6. PubMed ID: 22099521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synergistic effects of davercin, rifampicin, ethambutol and isonicotinic acid hydrazide on selected standard strains of Mycobacterium in the in-vitro and in-vivo experiments].
    Janowiec M; Andrzejczyk Z; Szwedowicz I
    Pneumonol Pol; 1988 Jun; 56(6):278-82. PubMed ID: 3226945
    [No Abstract]   [Full Text] [Related]  

  • 14. Pyrolysis mass spectrometry: a predictor of clinical response to treatment in pulmonary opportunist mycobacterial infection: preliminary work with M. malmoense.
    Heginbothom ML; Magee JT
    Zentralbl Bakteriol; 1997 Jan; 285(2):291-8. PubMed ID: 9060162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre evaluation of an automated BACTEC 960 system for susceptibility testing of Mycobacterium tuberculosis.
    Giampaglia CM; Martins MC; Vieira GB; Vinhas SA; Telles MA; Palaci M; Marsico AG; Hadad DJ; Mello FC; Fonseca Lde S; Kritski A
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):986-91. PubMed ID: 17705976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB.
    El-Sayed Zaki M; Goda T
    Tuberculosis (Edinb); 2007 Mar; 87(2):102-8. PubMed ID: 17035089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
    Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combination of gentamycin and amikacin with rifampicin, ethambutol and isoniazid on selected standard strains of Mycobacterium species in experiments done in vitro and in vivo].
    Janowiec M; Andrzejczyk Z; Marczewska J
    Pneumonol Pol; 1989 May; 57(5):300-7. PubMed ID: 2633149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
    Johansen IS; Thomsen VØ; Marjamäki M; Sosnovskaja A; Lundgren B
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):103-7. PubMed ID: 15474318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the nitrate-based colorimetric method for testing the susceptibility of Mycobacterium tuberculosis to streptomycin and ethambutol in liquid cultures.
    Syre H; Valvatne H; Sandven P; Grewal HM
    J Antimicrob Chemother; 2006 May; 57(5):987-91. PubMed ID: 16524896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.